Kannalife, Inc.

Kannalife, Inc. is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.

COMPANY INFORMATION

ADDRESS:

Pennsylvania Biotechnology Center
3805 Old Easton Road
Doylestown, PA 18902

PHONE:
(215) 695-6559

UPLOAD NEW PRESS RELEASE (log in required)

Log in to upload press releases

Featured in the following Articles:

Sarah Ratliff   |   February 24, 2020

Researching CBD – Looking for Limits

KANNALIFE, INC. Q&A

If you have any questions about Kannalife, Inc. or any of their products, please post them here.

0 Questions